The European Patent Office (EPO) has granted WEHI a patent for CISH knockout (KO) in Natural Killer (NK) cells which is exclusively licensed to ONK Therapeutics for cell immunotherapy purposes, giving ...
Background Chromogenic in situ hybridization (CISH) is fast becoming a well established technique for easy and sensitive determination of HER2 gene status in breast cancer. However, for the ...
NEW YORK and CAMBRIDGE, England, May 1, 2025 /PRNewswire/ -- Intima Bioscience, a clinical stage oncology company focused on curative intent in solid tumor cancers, presented data from a ...
Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC): Interim safety analysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results